Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say

The FDA is slated to make a decision on whether to approve Pfizer's shot in August before respiratory syncytial virus season in the fall. 

from Health and Science https://ift.tt/A1R9rzl
https://ift.tt/kgBT3nd
https://ift.tt/qEmn8Nj